ES3018358T3 - Régimen de dosificación que comprende un antagonista de la hormona liberadora de gonadotropina para tratar fibromas uterinos y reducir la pérdida de sangre menstrual - Google Patents

Régimen de dosificación que comprende un antagonista de la hormona liberadora de gonadotropina para tratar fibromas uterinos y reducir la pérdida de sangre menstrual Download PDF

Info

Publication number
ES3018358T3
ES3018358T3 ES18731976T ES18731976T ES3018358T3 ES 3018358 T3 ES3018358 T3 ES 3018358T3 ES 18731976 T ES18731976 T ES 18731976T ES 18731976 T ES18731976 T ES 18731976T ES 3018358 T3 ES3018358 T3 ES 3018358T3
Authority
ES
Spain
Prior art keywords
weeks
day
days
patient
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES18731976T
Other languages
English (en)
Spanish (es)
Inventor
Ernest Loumaye
Jean-Pierre Gotteland
Oliver Pohl
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kissei Pharmaceutical Co Ltd
Original Assignee
Kissei Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kissei Pharmaceutical Co Ltd filed Critical Kissei Pharmaceutical Co Ltd
Application granted granted Critical
Publication of ES3018358T3 publication Critical patent/ES3018358T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
ES18731976T 2017-06-05 2018-06-05 Régimen de dosificación que comprende un antagonista de la hormona liberadora de gonadotropina para tratar fibromas uterinos y reducir la pérdida de sangre menstrual Active ES3018358T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762515232P 2017-06-05 2017-06-05
PCT/EP2018/064767 WO2018224497A1 (en) 2017-06-05 2018-06-05 Gonadotropin-releasing hormone antagonist dosing regimens for treating uterine fibroids and reducing menstrual blood loss

Publications (1)

Publication Number Publication Date
ES3018358T3 true ES3018358T3 (es) 2025-05-16

Family

ID=62636157

Family Applications (1)

Application Number Title Priority Date Filing Date
ES18731976T Active ES3018358T3 (es) 2017-06-05 2018-06-05 Régimen de dosificación que comprende un antagonista de la hormona liberadora de gonadotropina para tratar fibromas uterinos y reducir la pérdida de sangre menstrual

Country Status (18)

Country Link
US (2) US11759464B2 (enExample)
EP (2) EP4509173A3 (enExample)
JP (2) JP7292566B2 (enExample)
KR (1) KR102884301B1 (enExample)
CN (1) CN110996957A (enExample)
AU (2) AU2018280741B2 (enExample)
CA (1) CA3066188A1 (enExample)
DK (1) DK3634419T3 (enExample)
EA (1) EA201992812A1 (enExample)
ES (1) ES3018358T3 (enExample)
FI (1) FI3634419T3 (enExample)
HR (1) HRP20250390T1 (enExample)
HU (1) HUE070907T2 (enExample)
MX (2) MX2019014482A (enExample)
PL (1) PL3634419T3 (enExample)
PT (1) PT3634419T (enExample)
SG (1) SG11201911599XA (enExample)
WO (1) WO2018224497A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL241595B2 (en) 2013-03-15 2025-10-01 Abbvie Inc Composition for use in methods of treating heavy menstrual bleeding associated with uterine fibroids
EP3634418A1 (en) 2017-06-05 2020-04-15 ObsEva S.A. Gonadotropin-releasing hormone antagonist dosing regimens for the treatment of endometriosis
US11759464B2 (en) 2017-06-05 2023-09-19 Kissei Pharmaceutical Co., Ltd. Gonadotropin-releasing hormone antagonist dosing regimens for treating uterine fibroids and reducing menstrual blood loss
AU2018419533A1 (en) 2018-04-19 2020-11-12 Abbvie Inc. Methods of treating heavy menstrual bleeding
JP2021532160A (ja) * 2018-08-01 2021-11-25 アッヴィ・インコーポレイテッド エラゴリックスに関する投与計画
WO2020089190A2 (en) 2018-10-29 2020-05-07 ObsEva S.A. Compositions and methods for the treatment of adenomyosis and rectovaginal endometriosis
KR20210100623A (ko) * 2018-11-07 2021-08-17 옵스에파 에스에이 에스트로겐-의존성 장애의 치료를 위한 조성물 및 방법
US20220288154A1 (en) * 2019-08-08 2022-09-15 ObsEva S.A. Gnrh antagonists for the treatment of estrogen-dependent disorders
KR20220061120A (ko) * 2019-08-08 2022-05-12 옵스에파 에스에이 에스트로겐-의존성 장애 치료용 조성물 및 방법
KR20210155350A (ko) 2020-06-15 2021-12-22 한상왕 녹차 추출물 및 비타민 d3를 유효성분으로 포함하는 자궁근종 개선용 조성물
CN115232144B (zh) * 2021-04-22 2024-04-02 长春金赛药业有限责任公司 含氮稠环类衍生物、药物组合物及其制备方法和应用
KR102738115B1 (ko) 2024-03-25 2024-12-05 한상왕 자궁근종 예방, 개선 또는 치료용 약학 조성물

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7109171B2 (en) 2000-02-28 2006-09-19 Praecis Pharmaceuticals Inc. Methods for treating FSH related conditions with GnRH antagonists
PT1939204E (pt) * 2005-10-19 2013-03-14 Kissei Pharmaceutical Derivado heterocíclico fundido, composição medicinal contendo o mesmo, e sua utilização medicinal
EP2535342B1 (en) * 2010-02-10 2014-08-06 Kissei Pharmaceutical Co., Ltd. Salt of fused heterocyclic derivative and crystal thereof
JP6268093B2 (ja) 2012-09-14 2018-01-24 キッセイ薬品工業株式会社 縮合複素環誘導体の製造方法およびその製造中間体
IL241595B2 (en) 2013-03-15 2025-10-01 Abbvie Inc Composition for use in methods of treating heavy menstrual bleeding associated with uterine fibroids
AU2017309015B2 (en) 2016-08-08 2022-09-15 Kissei Pharmaceutical Co., Ltd. Administration and dosage of therapeutic agent for endometriosis
SMT202200254T1 (it) 2016-09-30 2022-07-21 Takeda Pharmaceuticals Co Metodi di trattamento di fibromi uterini ed endometriosi
EP3634418A1 (en) 2017-06-05 2020-04-15 ObsEva S.A. Gonadotropin-releasing hormone antagonist dosing regimens for the treatment of endometriosis
US11759464B2 (en) 2017-06-05 2023-09-19 Kissei Pharmaceutical Co., Ltd. Gonadotropin-releasing hormone antagonist dosing regimens for treating uterine fibroids and reducing menstrual blood loss
KR20210100623A (ko) 2018-11-07 2021-08-17 옵스에파 에스에이 에스트로겐-의존성 장애의 치료를 위한 조성물 및 방법

Also Published As

Publication number Publication date
EP3634419A1 (en) 2020-04-15
FI3634419T3 (fi) 2025-05-02
EP4509173A2 (en) 2025-02-19
HUE070907T2 (hu) 2025-07-28
AU2018280741B2 (en) 2023-12-21
HRP20250390T1 (hr) 2025-05-23
CA3066188A1 (en) 2018-12-13
KR20200024797A (ko) 2020-03-09
AU2024201694A1 (en) 2024-04-04
JP7292566B2 (ja) 2023-06-19
US11759464B2 (en) 2023-09-19
PL3634419T3 (pl) 2025-06-09
EP3634419B1 (en) 2025-01-29
KR102884301B1 (ko) 2025-11-11
DK3634419T3 (da) 2025-03-31
CN110996957A (zh) 2020-04-10
EA201992812A1 (ru) 2020-05-21
MX2023013582A (es) 2024-04-16
JP2020522525A (ja) 2020-07-30
JP2023078315A (ja) 2023-06-06
AU2018280741A1 (en) 2020-01-30
JP7485815B2 (ja) 2024-05-16
SG11201911599XA (en) 2020-01-30
US20240000785A1 (en) 2024-01-04
EP4509173A3 (en) 2025-06-04
PT3634419T (pt) 2025-04-04
MX2019014482A (es) 2020-08-17
US20200179390A1 (en) 2020-06-11
WO2018224497A1 (en) 2018-12-13

Similar Documents

Publication Publication Date Title
ES3018358T3 (es) Régimen de dosificación que comprende un antagonista de la hormona liberadora de gonadotropina para tratar fibromas uterinos y reducir la pérdida de sangre menstrual
US20240293414A1 (en) Gonadotropin-releasing hormone antagonist dosing regimens for the treatment of endometriosis
WO2020094698A2 (en) Compositions and methods for the treatment of estrogen-dependent disorders
KR20220045198A (ko) 에스트로겐-의존성 장애의 치료를 위한 gnrh 길항제
AU2020325655A1 (en) Compositions and methods for the treatment of estrogen-dependent disorders
EP3873465B1 (en) Compositions and methods for the treatment of adenomyosis and rectovaginal endometriosis
HK40116843A (en) Gonadotropin-releasing hormone antagonist dosing regimens for treating uterine fibroids and reducing menstrual blood loss
EA049129B1 (ru) Схемы применения антагониста гонадотропин-высвобождающего гормона для лечения миомы матки и уменьшения менструальной кровопотери
HK40027583B (en) Dosing regimen comprising a gonadotropin-releasing hormone antagonist for treating uterine fibroids and reducing menstrual blood loss
HK40027583A (en) Dosing regimen comprising a gonadotropin-releasing hormone antagonist for treating uterine fibroids and reducing menstrual blood loss
HK40059353B (en) Compositions and methods for the treatment of adenomyosis and rectovaginal endometriosis
HK40059353A (en) Compositions and methods for the treatment of adenomyosis and rectovaginal endometriosis
WO2020093089A1 (en) A method of treatment